St.-Antonius-Hospital gGmbH
- Address
- Dechant-Deckers-Strasse 8, 52249 Eschweiler, Germany
St.-Antonius-Hospital gGmbH - Oncology & Hematology Research Center
St.-Antonius-Hospital gGmbH is a comprehensive oncology and hematology research center conducting cutting-edge clinical trials across multiple cancer types. The institution specializes in investigating novel therapeutic combinations, personalized treatment approaches, and targeted immunotherapies for both solid tumors and hematologic malignancies.
- Breast Cancer: Triple-negative, HER2-positive, and hormone receptor-positive subtypes with focus on neoadjuvant and adjuvant therapies including immunotherapy combinations
- Hematologic Malignancies: Multiple myeloma, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, mantle cell lymphoma, and follicular lymphoma
- Precision Medicine: Dynamic marker-adjusted personalized therapy (ADAPT) trials and minimal residual disease (MRD)-guided treatment strategies
- Advanced Therapeutics: Investigation of antibody-drug conjugates, CDK4/6 inhibitors, BTK inhibitors, BCL-2 inhibitors, and novel immunotherapy combinations
The center demonstrates particular expertise in breast cancer research with multiple ADAPT protocol studies evaluating personalized treatment approaches based on molecular risk stratification. In hematology, the institution leads trials investigating autologous stem cell transplantation, targeted antibody therapies including isatuximab and daratumumab, and innovative combination regimens for multiple myeloma treatment. The research portfolio emphasizes reducing treatment-related toxicity while maintaining or improving efficacy through precision medicine strategies and novel agent combinations in both newly diagnosed and relapsed disease settings.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 58 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 58 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in St.-Antonius-Hospital gGmbH
lock Showing 1 of 22 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Adjuvant Dynamic Marker-Adjusted Personalized Therapy: Ribociclib Plus Endocrine Therapy Versus Chemotherapy in HR+/HER2- Early Breast Cancer | WSG Westdeutsche Studiengruppe GmbH | Phase III | Not Recruiting | Jul 2019 | — |
IMP list
lock Showing 1 of 58 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Isatuximab | 4 | Unknown | 2017-08-15 | 2024-04-03 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.